BMF-219 induces 2 complete responses in 5 AML patients with menin mutations in Phase I trial

Biomea Fusion, Inc.

2 of 5 relapsed/refractory AML patients with menin-dependent mutations achieved CRs at Dose Level 4 (500mg or 125mg QD).
CRs observed within first two 28-day cycles; both patients continue on BMF-219 treatment.
No dose-limiting toxicities or QTc prolongation reported; generally well tolerated.
Dose Level 5 enrollment commenced to explore optimal biological dose.
Biomea plans to present additional data at an upcoming medical conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.